# Satellos Gets Patent for Muscle Regeneration Drug

> Satellos wins U.S. patent for forazapadin, a drug targeting muscle regeneration in degenerative diseases.
- Title: Satellos Gets Patent for Muscle Regeneration Drug | Shortify
- Summary: Satellos wins U.S. patent for forazapadin, a drug targeting muscle regeneration in degenerative diseases. Satellos Bioscience received U.S. patent No…
- Keywords: satellos, forazapadin, duchenne muscular dystrophy, fshd, phase 2, muscle regeneration, money, business, Gets, Patent, Muscle, Regeneration
- Source: Financialpost — https://financialpost.com/globe-newswire/satellos-granted-composition-of-matter-patent-for-forazapadin
- Read time: 1 min
- Topics: satellos, forazapadin, duchenne muscular dystrophy, fshd, phase 2, muscle regeneration, money, business
## Satellos Receives U.S. Patent
Satellos Bioscience Inc. received U.S. Patent No. 12,747,245 for forazapadin, a drug candidate targeting muscle regeneration in degenerative diseases.
## Patent Covers Muscle Regeneration Platform
The patent includes composition of matter claims for forazapadin and a broader class of AAK1 inhibitors within Satellos' muscle regeneration platform.
## Patent Protection Through 2044
The composition of matter patent provides intellectual property protection through September 6, 2044, with potential extension after U.S. marketing approval.
## CEO Highlights Patent Benefits
Frank Gleeson, Satellos' CEO, stated the patent supports long-term development and commercialization for forazapadin in degenerative muscle diseases.
## Forazapadin Targets Muscle Regeneration
Forazapadin inhibits AAK1, a protein that helps restore muscle regeneration biology disrupted in degenerative conditions.
## Next Steps for Forazapadin
Satellos plans to list the patent in the FDA's Orange Book after potential U.S. marketing approval for forazapadin.
## Key takeaway

Satellos Bioscience received U.S. patent No. 12,747,245 for forazapadin, a drug candidate targeting muscle regeneration in degenerative diseases.